Two years ago I created a screen to look for potential quality compounders – those rare high-quality companies that can generate consistently high returns for many years, reinvesting their profits successfully and potentially delivering long runs of market-beating growth.
The intervening period has seen periods of elevated volatility and some unexpected events. In this piece I want to look at the performance of my original selection and consider how this might be improved.
A quality compounding approach to investing requires fairly long timeframes. Two years isn’t really enough to see the benefits of true compounding. But I think it is enough to check which stocks from my original list are still performing and to look for some new contenders to consider.
Compounding Quality screen revisited
Before we go any further, here are the links to my original article and to the compounding quality screen itself.
As a quick refresher, here’s a snapshot of the screening rules I used to try and identify companies with the potential to be quality compounders:
When I originally looked at this screen in May 2023, it generated 35 stocks.
At the time of writing (16 July 2025), there are only 20 stocks in the results.
Of these, 12 remain from the original May ‘23 selection and eight are new.
How did the 2023 vintage perform?
I’ll return to the latest screen results shortly, but first I want to take a look at how my original selection has performed over the last two years or so.
To model the aggregate performance of the whole selection, I created a model portfolio with equally-sized starting positions.
The results are pretty underwhelming. My selection has largely just tracked the FTSE All Share index since May 23, with both achieving a capital gain of around 16%:
The reason for this humdrum performance becomes clear when we look at the range of share price performance from the 35 stocks in the portfolio. While there were some big winners, there were some notable losers as well, including a near-total loss with Argentex:
One selection of stocks over a two-year period isn’t a scientifically rigorous test of an investment method. But this clearly…